Rare diseases
Investigational molecules
Locations
Study on Durvalumab and Tremelimumab for Patients with Kidney Cancer at Risk of Recurrence After Surgery
FranceStudy on the Effectiveness of Durvalumab for Patients with Metastatic Breast Cancer in Early Chemotherapy Stages
FranceStudy on Durvalumab and Tremelimumab for Liver Cancer Patients Undergoing Electroporation Ablation
FranceStudy on Durvalumab and Radiotherapy for Patients with Early-Stage Non-Small Cell Lung Cancer
The NetherlandsStudy of Durvalumab, Cisplatin, Carboplatin, and Etoposide for Patients with Extensive Stage Small Cell Lung Cancer
GermanyPhase II Randomized Trial of Adjuvant Durvalumab Immunotherapy After Neoadjuvant Chemoimmunotherapy in Patients With Resectable Non‑Small Cell Lung Cancer
DenmarkFluorescence bronchoscopy to assess durvalumab-680LT distribution in unresectable stage III non‑small cell lung cancer patients after chemoradiation
The NetherlandsDurvalumab after chemoradiation for patients with limited‑stage small cell lung cancer: a randomized trial of high‑dose versus standard thoracic radiation
DenmarkAdvanced hepatocellular carcinoma patients: assessing atezolizumab drug combination and other treatment sequences
ItalyDurvalumab personalized consolidation immunotherapy after chemoradiotherapy in patients with stage III non‑small cell lung cancer
FranceStudy of IDE849, IDE‑161 and durvalumab evaluating safety and efficacy in patients with DLL3‑positive tumors including small cell lung cancer
FrancePhase 2 Study of Durvalumab + Tremelimumab with Lenvatinib vs Durvalumab + Tremelimumab Alone in Patients with Unresectable Hepatocellular Carcinoma
ItalyTell us about your condition – we search every trial in Europe and connect you with the right site.
